Advances in stem cell therapy against gliomas

Trends in Molecular Medicine

Volumn 19, Issue 5, 2013, Pages 281-291

  Bovenberg, M Sarah S ^a,b,c   Degeling, M Hannah ^a,b,c   Tannous, Bakhos A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cell therapy; Clinical trials; Gene therapy; Glioma; Hematopoietic stem cells; Mesenchymal stem cells; Neural stem cells; Oncolytic virus; Prodrug

Indexed keywords

5' NUCLEOTIDASE; ADAPALENE; CD146 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR4; ENDOGLIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GANCICLOVIR; INTERLEUKIN 10; INTERLEUKIN 8; KRUPPEL LIKE FACTOR 4; LANATOSIDE C; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; STROMAL CELL DERIVED FACTOR 1ALPHA; SUPERPARAMAGNETIC IRON OXIDE; THY 1 ANTIGEN; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN;

ATAXIA TELANGIECTASIA; BLOOD BRAIN BARRIER; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CYTOKINE RELEASE; FOLLOW UP; GENE EXPRESSION; GLIOMA; HUMAN; IMMUNOGENICITY; MESENCHYMAL STEM CELL; NONHUMAN; PATIENT SAFETY; PATIENT SELECTION; REVIEW; STEM CELL TRANSPLANTATION; TROPISM;

ANIMALS; COMBINED MODALITY THERAPY; GENETIC THERAPY; GLIOMA; HUMANS; STEM CELL TRANSPLANTATION; STEM CELLS; TISSUE THERAPY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84877120542     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.03.001     Document Type: Review

References (91)

1. Johnson D.R., et al. Conditional probability of long-term survival in glioblastoma: a population-based analysis. Cancer 2012, 118:5608-5613.
2. Grossman S.A., et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res. 2010, 16:2443-2449.
3. Furnari F.B., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007, 21:2683-2710.
4. Hochberg F.H., Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980, 30:907-911.
5. Okamoto Y., et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004, 108:49-56.
6. Calabrese C., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
7. Singh S.K., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
8. Bao S., et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006, 66:7843-7848.
9. Chalmers A.J. Radioresistant glioma stem cells - therapeutic obstacle or promising target?. DNA Repair (Amst.) 2007, 6:1391-1394.
10. Aboody K.S., et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:12846-12851.
11. Joo K.M., et al. Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol. Ther. 2009, 17:570-575.
12. Aboody K.S., et al. Development of a tumor-selective approach to treat metastatic cancer. PLoS ONE 2006, 1:e23.
13. Einstein O., Ben-Hur T. The changing face of neural stem cell therapy in neurologic diseases. Arch. Neurol. 2008, 65:452-456.
14. Ahmed A.U., et al. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol. Ther. 2011, 19:1714-1726.
15. Picinich S.C., et al. The therapeutic potential of mesenchymal stem cells. Cell- and tissue-based therapy. Expert Opin. Biol. Ther. 2007, 7:965-973.
16. Caplan A.I. Why are MSCs therapeutic? New data: new insight. J. Pathol. 2009, 217:318-324.
17. Jones B.J., McTaggart S.J. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp. Hematol. 2008, 36:733-741.
18. Keller G. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev. 2005, 19:1129-1155.
19. Germano I.M., et al. Gene delivery by embryonic stem cells for malignant glioma therapy: hype or hope?. Cancer Biol. Ther. 2008, 7:1341-1347.
20. Gerecht-Nir S., Itskovitz-Eldor J. Human embryonic stem cells: a potential source for cellular therapy. Am. J. Transplant. 2004, 4(Suppl. 6):51-57.
21. Tabatabai G., et al. Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. Brain 2005, 128:2200-2211.
22. Tabatabai G., et al. VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells. Brain 2008, 131:2579-2595.
23. Hingtgen S.D., et al. A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy. Stem Cells 2010, 28:832-841.
24. Sasportas L.S., et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:4822-4827.
25. Menon L.G., et al. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009, 27:2320-2330.
26. Kauer T.M., et al. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat. Neurosci. 2012, 15:197-204.
27. Bagci-Onder T., et al. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res. 2011, 71:154-163.
28. Balyasnikova I.V., et al. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. Cancer Lett. 2011, 310:148-159.
29. Badr C.E., et al. Suicidal gene therapy in an NF-κB-controlled tumor environment as monitored by a secreted blood reporter. Gene Ther. 2011, 18:445-451.
30. Badr C.E., et al. Functional drug screening assay reveals potential glioma therapeutics. Assay Drug Dev. Technol. 2011, 9:281-289.
31. Shah K., et al. Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Res. 2004, 64:3236-3242.
32. Choi S.A., et al. Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma. Neuro Oncol. 2011, 13:61-69.
33. Ryu C.H., et al. Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells. Hum. Gene Ther. 2011, 22:733-743.
34. Takamiya Y., et al. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J. Neurosci. Res. 1992, 33:493-503.
35. Rath P., et al. Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas. Curr. Stem Cell Res. Ther. 2009, 4:44-49.
36. Ezzeddine Z.D., et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 1991, 3:608-614.
37. Lee S.J., et al. Combined treatment of tumor-tropic human neural stem cells containing the CD suicide gene effectively targets brain tumors provoking a mild immune response. Oncol. Rep. 2011, 25:63-68.
38. Ryu C.H., et al. Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma. Biochem. Biophys. Res. Commun. 2012, 421:585-590.
39. Fei S., et al. The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model. J. Cancer Res. Clin. Oncol. 2012, 138:347-357.
40. Kosaka H., et al. Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma. Cancer Gene Ther. 2012, 19:572-578.
41. Kim J.H., et al. Therapeutic effect of genetically modified human neural stem cells encoding cytosine deaminase on experimental glioma. Biochem. Biophys. Res. Commun. 2012, 417:534-540.
42. Lim S.H., et al. Therapeutic targeting of subdural medulloblastomas using human neural stem cells expressing carboxylesterase. Cancer Gene Ther. 2011, 18:817-824.
43. Zhao D., et al. Human neural stem cell tropism to metastatic breast cancer. Stem Cells 2012, 30:314-325.
44. Folkins C., et al. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res. 2009, 69:7243-7251.
45. Yin J., et al. hMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence. Mol. Ther. 2011, 19:1161-1169.
46. Choi S.A., et al. Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas. Eur. J. Cancer 2012, 48:129-137.
47. van Eekelen M., et al. Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene 2010, 29:3185-3195.
48. Thaci B., et al. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther. 2012, 19:431-442.
49. Roger M., et al. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials 2010, 31:8393-8401.
50. Roger M., et al. Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. Int. J. Pharm. 2012, 423:63-68.
51. Li L., et al. Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. ACS Nano 2011, 5:7462-7470.
52. Ahmed A.U., Lesniak M.S. Glioblastoma multiforme: can neural stem cells deliver the therapeutic payload and fulfill the clinical promise?. Expert Rev. Neurother. 2011, 11:775-777.
53. Panciani P.F., et al. Stem cells based therapy in high grade glioma: why the intraventricular route should be preferred?. J. Neurosurg. Sci. 2012, 56:221-229.
54. Bexell D., et al. Rat multipotent mesenchymal stromal cells lack long-distance tropism to 3 different rat glioma models. Neurosurgery 2012, 70:731-739.
55. Bexell D., et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol. Ther. 2009, 17:183-190.
56. Pan L., et al. Viability and differentiation of neural precursors on hyaluronic acid hydrogel scaffold. J. Neurosci. Res. 2009, 87:3207-3220.
57. Teng Y.D., et al. Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:3024-3029.
58. Flight M.H. Drug delivery: encapsulation improves therapeutic stem cell action. Nat. Rev. Drug Discov. 2012, 11:106.
59. Park S.A., et al. CXCR4-transfected human umbilical cord blood-derived mesenchymal stem cells exhibit enhanced migratory capacity toward gliomas. Int. J. Oncol. 2011, 38:97-103.
60. Luo Y., et al. Functional SDF1α/CXCR4 signaling in the developing spinal cord. J. Neurochem. 2005, 93:452-462.
61. Bakondi B., et al. SDF-1α secreted by human CD133-derived multipotent stromal cells promotes neural progenitor cell survival through CXCR7. Stem Cells Dev. 2011, 20:1021-1029.
62. Kim S.M., et al. CXC chemokine receptor 1 enhances the ability of human umbilical cord blood-derived mesenchymal stem cells to migrate toward gliomas. Biochem. Biophys. Res. Commun. 2011, 407:741-746.
63. Velpula K.K., et al. The homing of human cord blood stem cells to sites of inflammation: unfolding mysteries of a novel therapeutic paradigm for glioblastoma multiforme. Cell Cycle 2012, 11:2303-2313.
64. Germano I.M., et al. Apoptosis in human glioblastoma cells produced using embryonic stem cell-derived astrocytes expressing tumor necrosis factor-related apoptosis-inducing ligand. J. Neurosurg. 2006, 105:88-95.
65. Lee E.X., et al. Glioma gene therapy using induced pluripotent stem cell derived neural stem cells. Mol. Pharm. 2011, 8:1515-1524.
66. Zhao Y., et al. Targeted suicide gene therapy for glioma using human embryonic stem cell-derived neural stem cells genetically modified by baculoviral vectors. Gene Ther. 2012, 19:189-200.
67. Varma N.R., et al. Endothelial progenitor cells (EPCs) as gene carrier system for rat model of human glioma. PLoS ONE 2012, 7:e30310.
68. Noyan F., et al. Induced transgene expression for the treatment of solid tumors by hematopoietic stem cell-based gene therapy. Cancer Gene Ther. 2012, 19:352-357.
69. Shah A.H., et al. Suppression of tumor metastasis by blockade of transforming growth factor β signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res. 2002, 62:7135-7138.
70. Brown A.B., et al. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum. Gene Ther. 2003, 14:1777-1785.
71. Liu J., et al. Rat bone marrow mesenchymal stem cells undergo malignant transformation via indirect co-cultured with tumour cells. Cell Biochem. Funct. 2012, 30:650-656.
72. Amariglio N., et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009, 6:e1000029.
73. Djouad F., et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102:3837-3844.
74. Houghton J., et al. Gastric cancer originating from bone marrow-derived cells. Science 2004, 306:1568-1571.
75. Spaeth E.L., et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE 2009, 4:e4992.
76. Karnoub A.E., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
77. Kucerova L., et al. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol. Cancer 2010, 9:129.
78. Nakamura K., et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 2004, 11:1155-1164.
79. Ahmed A.U., et al. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol. Pharm. 2011, 8:1559-1572.
80. Doucette T., et al. Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma model. Neoplasia 2011, 13:716-725.
81. Thu M.S., et al. Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model. PLoS ONE 2009, 4:e7218.
82. Menon L.G., et al. Imaging of human mesenchymal stromal cells: homing to human brain tumors. J. Neurooncol. 2012, 107:257-267.
83. Louis D.N., et al. Focus on central nervous system neoplasia. Cancer Cell 2002, 1:125-128.
84. Cairncross G., et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 1994, 12:2013-2021.
85. Aboody K., et al. Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta stone. Neuron 2011, 70:597-613.
86. Tabatabai G., et al. Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach?. Discov. Med. 2011, 11:529-536.
87. Yuan S.H., et al. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS ONE 2011, 6:e17540.
88. Zhang S.C., et al. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat. Biotechnol. 2001, 19:1129-1133.
89. - progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells. Blood 1999, 93:96-106.
90. Higuchi A., et al. Biomaterials for the feeder-free culture of human embryonic stem cells and induced pluripotent stem cells. Chem. Rev. 2011, 111:3021-3035.
91. Tran C.T., et al. Differential expression of MHC class II molecules by microglia and neoplastic astroglia: relevance for the escape of astrocytoma cells from immune surveillance. Neuropathol. Appl. Neurobiol. 1998, 24:293-301.